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Tuberculosis (TB) has tremendous public health relevance. It most frequently affects
the lung and is characterized by the development of unique tissue lesions, termed
granulomas. These lesions encompass various immune populations, with macrophages
being most extensively investigated. Myeloid derived suppressor cells (MDSCs) have
been recently identified in TB patients, both in the circulation and at the site of infection,
however their interactions with Mycobacterium tuberculosis (Mtb) and their impact on
granulomas remain undefined. We generated human monocytic MDSCs and observed
that their suppressive capacities are retained upon Mtb infection. We employed an in
vitro granuloma model, which mimics human TB lesions to some extent, with the aim
of analyzing the roles of MDSCs within granulomas. MDSCs altered the structure of and
affected bacterial containment within granuloma-like structures. These effects were partly
controlled through highly abundant secreted IL-10. Compared to macrophages, MDSCs
activated primarily the NF-κB and MAPK pathways and the latter largely contributed to
the release of IL-10 and replication of bacteria within in vitro generated granulomas.
Moreover, MDSCs upregulated PD-L1 and suppressed proliferation of lymphocytes,
albeit with negligible effects on Mtb replication. Further comprehensive characterization
of MDSCs in TB will contribute to a better understanding of disease pathogenesis and
facilitate the design of novel immune-based interventions for this deadly infection.
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INTRODUCTION
Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis (TB), a disease that
accounted for 1.7 million deaths in 2016 (1). Caseous granulomas which develop at the site ofMtb
infection are considered a hallmark of pulmonary TB (2). Albeit specific for TB, these lesions are
not pathognomonic, granulomas are triggered also by unrelated bacteria, fungi and parasites as well
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as by foreign bodies (3). The cellular composition of TB
granulomas may vary with disease stage. Generally, lesions
consist of macrophages, lymphocytes and transformed
macrophages, including epithelioid and multinucleated giant
cells as well as foamy macrophages (4, 5). Trajectories and the
fate of granulomas are determined by a plethora of secreted
factors, such as cytokines and eicosanoids, which are locally
produced by immune cells (6), in situ changes in cellular
composition, as well as viability, replicative and metabolic
features of the mycobacteria (7, 8). Balanced abundances of the
pro-inflammatory cytokines IFN-γ and TNF-α are associated
with bacterial clearance while regulatory cytokines like IL-10
offer limited protection to TB (2, 9, 10). Presence of selected
immune cell subsets, their location, as well as their propensity to
produce soluble mediators thus control stability of granulomas
and TB progression.
Despite recent new insights into mechanisms governing
Mtb interaction with immune cells, understanding of factors
controlling Mtb survival within pulmonary TB granulomas,
specifically in human lesions remains poorly defined (7). The
diversity and the activation spectra of immune cells present
within granulomas are currently acknowledged (11, 12). Yet,
how newly described subsets imprint on granuloma stability
and Mtb replication remains to be established. Myeloid-derived
suppressor sells (MDSCs) have been recently detected in pleural
effusion and in the peripheral blood in TB patients (13–
15). MDSCs encompass heterogeneous myeloid cells, both
monocytic- and neutrophil-like, which suppress T-cell immunity
through high expression of arginase-1, inducible nitric oxide
synthase, indoleamine dioxygenase, cyclooxygenase, IL-10 or
reactive oxygen species (16). In murine models, MDSCs harbor
mycobacteria, promote tissue damage and their depletion alone
or in combination with canonical TB chemotherapy lowers
bacillary burdens and improves pathology (17–21). These studies
have identified MDSCs within the lungs and highlighted their
capacity to alter or directly produce and respond to cytokines
critical for granuloma stability, notably IFN-γ, TNF-α, IL-10, and
IL-6 (13–15, 17–23). Moreover, investigations performed in the
non-human primate model report populations of macrophages
co-expressing nitric oxide synthase and arginase-1 (24). Such
cells resemble MDSCs and were detected specifically in necrotic
granulomas in macaques. The interactions of human MDSCs
with Mtb including their ability to modulate granuloma-like
structures have not been addressed so far.
Murine models represent valuable tools to study host-
mycobacteria interactions (25). However, the extent of similarity
between disease pathophysiology and lung lesions in murine TB
and human patients varies with the murine model utilized (26).
Particularly TB granulomas are hardly reproduced by TB mouse
lung lesions. To overcome such experimental limitations many
investigators have independently developed and characterized
in vitro granuloma models (27–38). Such structures enable
the study of human cell-cell interactions upon mycobacterial
infection and thereby early events in TB. Absence of unique lung
environment and lack of fibrosis, encapsulation and caseation
represent major limitations of such models. However, these
structures mimic human TB granulomas especially regarding
the cellular composition. In vitro granulomas contain epithelioid
cells, foamy macrophages and multinucleated giant cells, along
with other immune cells usually observed in TB lesions (32).
Considering the limitations of this model, we termed such in
vitro generated multicellular aggregates, “in vitro granuloma like
structures” (IVGLSs). We investigated the functions of human
monocytic MDSCs in TB by characterizing their responses to
mycobacteria and using a well-defined in vitro granuloma model
(35). We observed that MDSCs support Mtb replication within
IVGLSs and identified molecular requirements and signaling
pathways operative in MDSCs and driving such effects.
MATERIALS AND METHODS
Isolation and Culture of Cells
The buffy coats were obtained from healthy donors through
the blood bank of German Red Cross (Deutsches Rotes Kreuz,
DRK). Donors were kept anonymous and their latent TB status
was unknown. Peripheral blood mononuclear cells (PBMCs)
were isolated from buffy coats by density gradient centrifugation
(Biocoll, Biochrom GmbH, DE). After thorough washing with
phosphate buffer saline (PBS), mononuclear cells were cultured,
cryopreserved or further processed according to the requirement
of each experiment.
Generation of human MDSCs was done as previously
described (39). Briefly, CD14+ cells were isolated from the
PBMC fraction by positive magnetic bead isolation according
to manufacturer’s instructions (Miltenyi Biotech, DE). 5 × 106
monocytes were cultured in untreated Petri dishes in 10ml
IMDM (Gibco, IRL) supplemented with heat inactivated 10%
(v/v) fetal calf serum (FCS) (Lonza Group, CH), 1% L-glutamine,
1% HEPES and 0.1% β-mercaptoethanol (β-ME) (Gibco, IRL),
recombinant IL-4 and GM-CSF (both at 1000 U/ml; PeproTech,
NJ, USA) and PGE2 (1µM; Sigma-Aldrich, MO, USA). Cell were
differentiated for 6 days at 37◦C and 5% CO2. This protocol
resulted in generation of loosely attachedMDSCs (39). In selected
experiments, for comparative analysis cells were differentiated in
presence of humanAB clotted serum (Sigma-Aldrich,MO,USA),
herein abbreviated hsMDSCs.
To generate monocyte-derived macrophages (MDMs), 2 ×
107 PBMCs were suspended in 10ml PBS and incubated for 1 h in
75 cm2 flask at 37◦C, 5% CO2. Afterwards cells were washed with
PBS and incubated with 20ml RPMI-1640 supplemented with 1%
L-glutamine, 1% HEPES, 0.1% β-ME and heat inactivated 10%
human AB clotted serum. Flasks were incubated for 6 days at
37◦C, 5% CO2. Harvesting of MDMs was done using accutase
(Gibco, IRL).
Whole PBMCs were cryopreserved in 10% dimethyl sulfoxide
(DMSO) in FCS at the day of isolation for further co-cultures
with IVGLSs obtained from matched donors in granuloma
studies. Similarly, CD14− cells or PBMCs were cryopreserved
from the matched donors for purification of untouched T-
cells using naïve pan T-cell isolation kit (Miltenyi Biotech, DE)
according to vendor’s instructions for further co-culture studies.
Isolation of MDSCs from active TB patient samples was done
as described previously (23). In brief, PBMCs were isolated
from blood within 2 h of collection using density gradient
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centrifugation. Unlabeled HLADR− cells were isolated using
HLADR microbeads (Miltenyi Biotech, DE) and subjected to
isolation of CD33+ cells using CD33+ microbeads (Miltenyi
Biotech, DE) according tomanufacturer’s instructions. Cells were
cultured in RPMI-1640 (Biowest, France) supplemented with 1%
L-glutamine and 2% FCS. Donors were negative for HIV and
positive for drug susceptible TB.
Cell viabilities were estimated after various assays using the
LDH cytotoxicity kit (Roche Holding AG, CH).
Bacterial Culture and Infection of MDSCs
and MDMs
M. tuberculosis laboratory strain H37Rv and M. bovis BCG
cultures were grown to early-log phase at 37◦C in Middlebrook
7H9 broth (Thermo-Fischer Scientific, NH, USA) supplemented
with 10% albumin dextrose catalase (Thermo-Fisher Scientific,
MA, USA), 0.05% glycerol and Tween 80 (Sigma-Aldrich, MO,
USA). Bacilli were used within four passages after thawing and
were harvested when cultures reached an optical density (at
600 nm) of 0.4 to 0.6. For infection, bacteria were washed with
PBS and passed through 27G needle to obtain a single cell
suspension. MDSCs and MDMs were infected at the multiplicity
of infection (MOI) 10 and 20 for 4 h in rotation at 37◦C to
minimize loss of cells due to poor adherence and to maintain
similar conditions for both cell types (17). The MOI 10 resulted
in 1 to 2 bacteria per cell at 4 h post infection (data not shown).
MOI 20 was used only for short course experiments.
Flow Cytometry
Cells were blocked with human Fc receptor (Miltenyi Biotech,
DE), stained and fixed with 4% paraformaldehyde (PFA) before
proceeding for acquisition. For each donor and each condition,
three technical replicates were processed. Following antibodies
were used: CD3 (clone UCHT1), CD8 (clone HIT8a), CD11b
(clone ICRF44), CD33 (clone WM53), CD14 (clone M5E2),
CD15 (clone H198), Lineage cocktail (CD3, CD19, CD20 and
CD56; clones UCHT1, HIB19, 2H7 and 5.1H11, respectively), Ki-
67 (clone Ki-67) and PD-L1 (clone 29E.2A3) from BioLegend,
CA, USA; CD4 (clone RPA-T4), HLA-DR (clone G46-6) and
AnnexinV from BD Biosciences, NJ, USA; live/dead staining
kit from Thermo-Fisher Scientific, MA, USA. In selected
studies, MDSCs, MDMs or T cells were labeled with 5µM
CFSE (CellTrace, Invitrogen, CA, USA) following manufacturer’s
instructions. All samples were acquired in the BSL3 facility on a
CytoFLEX flow cytometer (Beckman Coulter, CA, USA).
T-Cell Suppression Assay
[3H]-Thymidine incorporation assay was employed to assess
proliferation of T-cells in the BCG studies and the CFSE
dilution method as well as the Ki-67 staining were used for
the Mtb investigations. Each donor and conditions were studied
in triplicate. Lymphocytes were polyclonally activated in UV
sterilized flat bottom 96-well Maxisorb plates which were coated
with 1µg/ml of anti-CD3 (clone UCHT1) and anti-CD28
(clone 37407) (R&D Systems, MN, USA) antibodies in PBS.
Unstimulated T-cells served as negative control and stimulated
T-cells without addition of the MDSCs were used as positive
control. T-cells were co-cultured with varying amounts of
autologous naïve or BCG-infected MDSCs (MOI 10). Plates were
sealed with parafilm and incubated at 37◦C and 5% CO2. After
48 h of co-culture, 1µCi of [3H]-Thymidine was added and plates
were incubated for additional 18 h. Plates were either directly
read or stored at −20◦C for further harvesting. FilterMate
Harvester was used to quantify counts per minute (CPM) using a
Microplate Plate Counter (PerkinElmer, MA, USA). In separate
assays, cells were also stained with 7AAD and AnnexinV to
estimate numbers of live T-cells upon co-culture. Mtb infected
MDSCs were co-cultured in BSL3 laboratory with autologous T-
cells after prior labeling of the lymphocytes with CFSE. Similar
to BCG infection, MDSCs were infected with H37Rv at MOI 10
for 4 h and added to stimulated T-cells in various ratios. After
72 h of incubation at 37◦C and 5% CO2, cells were isolated and
processed for further assessment of the proliferation by staining
for phenotype and proliferation markers (CD3, CD4, and CD8;
Ki67) and analyzed by flow cytometry.
Generation of IVGLSs
The protocol for the generation of IVGLSs was adapted from
Agrawal et al. (35). In brief, 4 × 105 PBMCs were seeded on the
day of PBMC isolation in 48 well tissue culture treated plates.
Cells were incubated overnight in 10% FCS supplemented RPMI
GlutaMAX media (Thermo-Fisher Scientific, MA, USA). The
next day cells were infected with H37Rv at an MOI of 0.005
(calculated according to the total number of PBMCs cultured
per well, that is approximately 2,000 bacteria per well) followed
by incubation for 4 h and subsequent gentamicin (100 µg/ml)
treatment for 2 h to remove extracellular bacteria. Afterwards,
plates were centrifuged at 100 × g for 3min, media were
replaced with fresh 500 µl media per well and plates were
incubated until further testing. To assess the effect of different
cell types on IVGLSs; (a) MDSCs, (b) MDMs (both after 6 days
of differentiation) and (c) PBMCs (cryopreserved) were collected,
washed and added to running IVGLSs cultures at day 5 post
induction. Distinct ratios of MDSCs/MDMs/PBMCs compared
to the number of PBMCs employed for generation of IVGLSs
were used. Therefore, ratios 1:2 and 1:4 correspond to addition
of 2 × 105 or 1 × 105 cells at day 5 post induction, respectively,
where 4 × 105 PBMCs were seeded to induce IVGLSs at day 0.
In all of these co-culture studies MDSCs/MDMs/PBMCs were
kept uninfected while adding carefully to IVGLSs. Any further
readouts were done after 48 h of co-cultures, that is day 7 post
generation of the IVGLSs.
Quantification and Imaging of the IVGLSs
IVGLS plates were centrifuged at 100× g for 3min, supernatants
were removed and cells were fixed overnight in 4% PFA in PBS.
Next day PFAwas washed away and cells were stained with DAPI.
Images were acquired on the high content platform ArrayScan
XTI (Thermo-Fisher Scientific, MA, USA) and subsequently
analyzed using an in-built software, HCS Studio (Thermo-Fisher
Scientific, MA, USA). HCS analysis protocol was set to facilitate
identification of the individual objects, notably granuloma-
like structures, and to reject background noise. Reported valid
granulomas were equal or larger than 400µm2, which was lowest
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detection limit of the software for high specificity according to
our protocol. The same acquisition settings were applied to all
investigated samples. Each condition was acquired from triplicate
wells for each donor. IVGLSs were in addition induced on Poly-
L-Lysine coated coverslips to observe these structures, with or
without addition of MDSCs/MDMs, using confocal microscopy
(Leica TCS SP8; Leica Microsystems, DE). Giemsa staining
was performed using standard protocol (35) to observe cellular
structures in 48 well plates.
Estimation of Bacterial Colony Forming
Units (CFUs) From IVGLSs
Cell culture plates were centrifuged at 100 × g for 3min and
supernatants collected for further analyses. Cells were lysed with
100 µl of 0.1% Triton-X100 in PBST (0.05% Tween80 in PBS).
Serial dilution of lysates were plated on Middlebrook 7H11 agar
(Fischer Scientific, NH, USA) plates supplemented with 10%
oleic albumin dextrose catalase (Thermo-Fisher Scientific, MA,
USA) and 0.5% glycerol. Total CFUs were counted after 21
days of incubation at 37◦C. For contact dependency assessment,
transwells of 0.4µm pore sized polycarbonate inserts were used.
IVGLSs were generated in the lower chamber and MDSCs or
MDMswere added with or without inserts to these wells. Samples
were processed and plated for CFU enumeration after 48 h of
co-cultures.
Cytokine Measurements
Supernatants collected from various samples (monocultures and
co-cultures) were passed through 0.2µm pore size filters and
stored at −20◦C until used. Commercially available ELISA
kits from R&D Systems (MN, USA) were used to detect
concentrations of IL-6, IL-10, IFN-γ, and TNF-α according to
manufacturer’s instructions.
To assess the effect of specific inhibitors on cytokine release,
cells were pre-incubated for 1 h with several inhibitors at varying
concentrations (1, 5, or 30µM) and infected with Mtb at MOI
10 afterwards. For each cell type and each concentration of
inhibitor, internal controls with corresponding amount of DMSO
were included. The following inhibitors were used: SB203580
(p38 inhibitor) and PD98059 (MEK1/2 inhibitor) (Cell Signaling,
MA, USA); PD0325901 (MEK1/2 inhibitor), BMS345541 (NF-κB
inhibitor), FR180204 (ERK1/2 inhibitor), Tanshinone IIa (AP1
inhibitor) and LY294002 (PI3K inhibitor) (Sigma-Aldrich, MO,
USA); Wortmanin (PI3K inhibitor) (Merck-Calbiochem, DE)
and SR11302 (AP1 inhibitor) (Tocris Biosciences, Bristol, UK).
Supernatants were collected after 24 h of culture, filtered and
assessed for cytokine concentration.
To observe antigen specific responses, MDSCs purified from
TB patients were stimulated either with tuberculin protein
purified derivative (PPD) (Statens Serum Institute, Denmark)
at 4µg/ml or only media. According to other experimental
conditions, (data not included) co-stimulatory antibodies CD28
(clone L293) and CD49d (clone L25) (BD Biosciences, NJ, USA)
were also added to isolated MDSCs at 250 ng/ml. Cytokines
were measured from the supernatants after 20 h of culture using
multiplex bead based assay (IL-10 by R&D Systems Incorporated,
MP, USA and IL-6 by Merck, DE) on a Luminex platform
(Bio Rad laboratories, CA, USA). Culture interval also included
addition of Brefeldin A (Sigma-Aldrich, MO, USA) before 4 h
of completion of assay; to measure intracellular cytokines from
same samples (data not included).
Neutralization Assay
Two different neutralization experiments were independently
performed: (a) IL-10 and (b) PD-L1. For each assay, after
harvesting mature cells, MDSCs or MDMs were pre-incubated
with neutralizing antibodies for 30min, at 10µg/ml. The
following antibody clones were employed: IL-10 (clone 23738)
and IL-10Ra (clone 37607) (R&D Systems, MN, USA), PD-
L1 (clone MIH1, Thermo-Fisher Scientific, MA, USA), isotype
IgG1κ (clone MG1-45), and isotype IgG2bκ (clone MG2b-
57) (BioLegend, CA, USA). Afterwards cells were added to
day 5 IVGLSs of matched donors and analyzed after 48 hr
of co-cultures. Similarly, IVGLSs were treated with different
pathway inhibitors (SB203580, PD98059, BMS345541, LY294002,
Wortmanin and SR11302), as described in the above section, with
or without addition of MDSCs or MDMs at day 5 post induction
of IVGLSs. The CFUs were estimated after 48 h of co-culture.
RNA Expression and qRT-PCR
After 4 h ofMtb infection, 5 × 105 naïve or infected MDSCs and
MDMs were transferred in 1ml TRIzol reagent (Invitrogen, CA,
USA) and kept frozen at −80◦C until RNA isolation. Reverse
transcription was performed using High-Capacity cDNAReverse
Transcription Kit (Applied Biosystems, CA, USA). qRT-PCR
was analyzed on a Biomark HD System (Fluidigm Corporation,
CA, USA) with TaqMan Fast universal mix and primers. The
following primers were used: CCL5: Hs00982282_m1, CXCL10:
Hs01124251_g1, IL6: Hs00174131_m1, IL10: Hs00961622_m1,
PDL1: Hs00204257_m1, TGFB: Hs00998133_m1, and TNFA:
Hs01113624_g1.
Signal Pathway Analysis and Western
Blotting
Cells were rested in 1% FCS supplemented RPMI-1640 for 5 h
at 37◦C in a rolling incubator. Equal numbers of MDSCs and
MDMs (5 × 105 cells per condition) were stimulated either
with H37Rv (MOI 20) or with LPS (25 ng/ml) for various
time intervals ranging from 10min to 2 h. At every time point
cells were centrifuged at 300 × g, 4◦C for 5min followed by
two washings with cold PBS and incubation with RIPA buffer
(BD Biosciences, NJ, USA) supplemented with phosphatase and
protease inhibitor cocktail (Roche Holding AG, CH) at 4◦C for
10min. Supernatants were collected after centrifugation at 16,000
× g for 10min at 4◦C. Samples were denatured at 96◦C for 10min
after addition of sample buffer (Sigma-Aldrich, MO, USA) and
were either subjected to immediate electrophoresis or stored
at −80◦C. After electrophoresis and transfer to nitrocellulose
membrane, samples were blocked with 5% low fat milk in PBST
(0.1% Tween20 in PBS). Membranes were incubated overnight
with primary antibodies; NF-κB p65, NF-κB p-p65, p38 MAPK,
p-p38 MAPK, ERK1/2, p-ERK1/2, JNK, p-JNK (all from Cell
Signaling, MA, USA) at 4◦C. Subsequently, membranes were
Frontiers in Immunology | www.frontiersin.org 4 October 2018 | Volume 9 | Article 2417
Agrawal et al. M-MDSC Support M. tuberculosis Replication in Granulomas
incubated with the HRP-conjugated anti-mouse IgG or anti-
rabbit IgG antibodies (Cell Signaling, MA, USA) and developed
using ECL detection kit (Thermo-Fisher Scientific, MA, USA).
Statistical Analysis and Software
Data were analyzed with GraphPad Prism 7 (Graphpad, USA),
FlowJo (FlowJo LLC, OR, USA), HCS Studio (Thermo-Fisher
Scientific, MA, USA), Fiji ImageJ (Wayne Rasband, National
Institutes of Health, USA), Fluidigm Real-Time PCR analysis
software (Fluidigm Corporation, CA, USA), and R statistical
programming environment (40). The paired Student’s t-test was
applied to estimate statistical significance for most data sets. For
analysis of various treatments on a cell type, within a group,
one-way ANOVA with Dunn’s multiple comparison was applied.
RNA expression data was analyzed by two-way ANOVA followed
by Bonferroni correction. Comparison of the distributions of
granuloma sizes was performed using aWilcoxon test comparing
the distribution medians of each donor in two groups and
confirmed by a randomization test.
RESULTS
MDSCs Retain Their Suppressive Property
Upon Mtb Infection
The phenotype of in vitro differentiated MDSCs was examined
following the gating strategy suggested by Bronte et al.
(16) (Supplementary Figure 1). Cells were lineage negative
and expressed high CD33 and CD14. Differentiation of
MDSCs with human serum down-regulated CD14 expression
and left other cell surface markers unchanged (hsMDSCs;
Supplementary Figure 1). We validated the suppressive
abilities of in vitro generated human MDSCs (Figures 1A,B)
and observed that these properties were preserved upon
infection with virulent mycobacteria (Figures 1C,D;
Supplementary Figure 2). Mtb-infected MDSCs suppressed
proliferation of CD4+ (Figures 1C,E) and CD8+ (Figures 1D,F)
T-cells upon co-culture. The results of CFSE dilution
assay were confirmed by Ki-67 proliferation experiment
(Supplementary Figure 3A). Infection with BCG similarly
resulted in maintenance of the T-cell suppressive activity of
human MDSCs (Supplementary Figure 3B). The suppressive
capacity ofMtb-infected MDSCs was observed irrespective of the
sera used for their differentiation (Supplementary Figure 4A).
MDSCs generated with FCS were employed for further analyses,
unless otherwise indicated. Altogether, these co-culture studies
suggest that the suppressive property of MDSCs is retained upon
mycobacterial infection independent of key virulence factors,
such as those encoded by region of difference 1 (RD1), which
is absent in BCG. Suppression was maintained upon infection
implying that MDSCs can affect the cross-talk between T-cells
and myeloid cells in TB.
MDSCs Alter the Structure of and Mtb
Containment Within IVGLSs
With the knowledge of reports specifying important roles
of MDSCs at the site of infection (17, 20, 21), we wanted to
delineate the outcomes of MDSC suppression in a disease-
relevant setup. Effects of MDSCs on stability of in vitro
generated granuloma-like structures and bacterial containment
within these structures were ascertained. MDMs were used for
comparative analysis because they usually harborMtb and tissue
recruited inflammatory monocytes/macrophages share ontogeny
with MDSCs (41). We employed an in vitro model developed by
Agrawal et al. (35) and observed appearance of IVGLSs starting
day 5 post generation (Supplementary Figures 5A–D). Within
such structures, Mtb replicated upon extended incubation, as
indicated by increased bacterial loads at day 7 post induction
(Supplementary Figure 5E). This is in line with observations
in other IVGLSs (42). We selected day 5 IVGLSs to initiate
co-cultures with MDSCs/MDMs and observed responses 48 h
afterwards, which was day 7 post IVGLS induction. IVGLSs
became larger, yet less numerous, upon addition of MDSCs as
compared to MDMs (Figures 2A–J, Supplementary Figure 5F).
Addition of MDSCs to IVGLSs resulted in higher CFUs in
IVGLSs, compared to MDM co-cultures (Figure 2K). This
indicates that MDSCs facilitate Mtb growth or restrict anti-
bacterial mechanisms within IVGLS either by providing a
replication niche or by altering the microenvironment of the
granulomas. Similarly, hsMDSCs induced higher bacillary
loads in IVGLSs, albeit their propensity to enlarge these
multicellular structures was inconclusive because of heightened
variability among donors (Supplementary Figures 4B,C).
Although majority of added cells remained viable upon
extended co-culture with IVGLSs and apoptosis rates were
similar between the two cell types, frequencies of necrotic
MDSCs exceeded those of MDMs after 48 h of IVGLS co-
cultures (Supplementary Figure 6). The effects on granuloma
size and bacterial replication were more pronounced upon
addition of higher numbers of MDSCs in all assays that is
when ratio of MDSCs (added number):IVGLS (day 0 PBMCs
number) was 1:2. In murine pulmonary TB models frequency
of MDSCs at the site of infection parallels susceptibility to
disease (17) and in humans their number decreases upon
therapy (23). This was replicated in the IVGLS model
suggesting that higher MDSC numbers may correlate with
TB pathology in humans, possibly by tailoring in situ immune
responses.
IL-10 Neutralization Reduces
MDSCs-Induced Mtb Growth Within
IVGLSs
Stability of TB granulomas is positively regulated by TNF-αwhile
IFN-γ is rather associated with increased protection to TB (2,
43). The anti-inflammatory cytokine IL-10 impairs Mtb specific
immunity and promotes bacterial growth. The major sources of
this cytokine are not well defined, specifically within granulomas
(2, 44, 45). Modeling studies have suggested important roles of
IL-10 in granuloma progression via macrophage polarization
(46). We hypothesized that abundances of these cytokines
could be altered by MDSCs and that in turn affected bacillary
replication. Compared to MDMs, IL-10 levels in IVGLS
co-cultures were indeed higher upon addition of MDSCs
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FIGURE 1 | In vitro generated human MDSCs maintain suppressive activity following Mtb infection. Proliferation of polyclonally stimulated, CFSE-labeled T-cells
co-cultured with naïve (nMDSCs) (A,B) and Mtb-infected (MOI 10) MDSCs (iMDSCs) (C,D) for 72 h. Number of T-cells was kept constant for all conditions with varying
amounts of added MDSC; no MDSCs (0:1), 1/4th MDSCs (1:4) and equal MDSCs (1:1). Representative histograms are presented for one donor (E,F). Each symbol
corresponds to a single donor, shown are median±IQR. Data are pooled from 2 independent experiments (n = 6 individuals); paired Student’s t-test, **p ≤ 0.01, ***p
≤ 0.001, ****p ≤ 0.0001.
(Figure 3A). Concentration of IL-6 remained unchanged,
although it is known to be released by MDSCs (17) and
abundances of the pro-inflammatory cytokines TNF-α and IFN-
γ, were also not significantly different in IVGLSs supplemented
with MDSCs compared to MDMs. The amounts of TNF-α
and IFN-γ positively correlate with IVGLSs size (35), however
these cytokines were not altered by any of the cells added
to IVGLSs in our study. To investigate whether IL-10 was
critical for Mtb replication within IVGLSs co-cultured with
MDSCs, we employed neutralizing antibodies. Combination of
antibodies against IL-10 and IL-10 receptor A reduced bacterial
growth compared with cultures receiving the isotype controls,
specifically in MDSC treated IVGLSs (Figure 3B). We assume
that an environment characterized by abundant IL-10 partially
explains the mycobacteria promoting activity of MDSCs.
MDSCs Secrete Differential Amounts of
Inflammatory and Regulatory
Cytokines/Chemokines Compared to
MDMs After Mtb Infection
Murine MDSCs release both inflammatory and regulatory
cytokines uponMtb challenge, which prompted us to investigate
how differential the source of IL-10, as observed in IVGLSs,
was in human MDSCs. We profiled various immune relevant
cytokines in MDMs and MDSCs infected with mycobacteria.
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FIGURE 2 | MDSCs alter the structure and bacterial containment of in vitro granuloma like structures (IVGLSs) induced by Mtb infection. Images captured using
Arrayscan at day 7 of cultures after staining with Giemsa (A–C) or with the nuclear dye DAPI (D–F). Images from uninfected wells (A,D) treated similarly to the
Mtb-induced IVGLS wells (B,C,E,F). Images represent IVGLS wells co-cultured for 48 h with MDSCs (B,E) or with MDMs (C,F). (G,H) Bright field images of day 7
IVGLSs acquired with a confocal microscope. Z-stacked image of 30 focal planes (H). Number and size of IVGLSs (I,J) and bacterial colony forming units (CFUs) (K)
in IVGLSs at day 7 post generation and after co-culturing for the last 48 h with indicated cell subsets at distinct ratios. Added cells were at two ratios; 1:2 and 1:4
(added cells:number of PBMCs seeded for generation of IVGLSs). Each symbol corresponds to a single donor, shown are median±IQR. Data are from 5 independent
experiments (n = 11–14 individuals) (representative for A–H and pooled for I,J) and from 3 independent experiments (pooled, n = 8 individuals) (K); paired Student’s
t-test if not otherwise mentioned in figure, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
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FIGURE 3 | IL-10 promotes MDSC-driven bacterial replication in IVGLSs. (A) Cytokines from cell-free supernatants of IVGLSs at 48 h of co-cultures. (B) Bacterial
burden at day 7 IVGLSs and after co-culturing with MDSCs/MDMs for the last 48 h and simultaneous IL-10 neutralization, all antibodies were used at 10µg/ml.
IVGLSs and IVGLSs co-cultured with MDSCs/MDMs contain different total cell numbers, hence data are separated by dotted line. Each symbol corresponds to a
single donor, shown are median±IQR. Data are pooled from 3 independent experiments (n = 9 individuals) (A) and 4 independent experiments (n = 11 individuals)
(B); paired Student’s t-test, *p ≤ 0.05, **p ≤ 0.01.
mRNA expression of IL10 and IL6 was higher in infected
MDSCs than in MDMs (Figure 4A), whereas transcripts for
TNFA were comparable in the two cell types. We measured
the expression level of TGF-β in addition to IL-10 as these
cytokines are known to be expressed synergistically (47).
Surprisingly, the expression of TGFB was lower in MDSCs.
We monitored transcription of chemokines as these regulate
recruitment of immune cells to sites of infection and could
impact on dynamics of cells within granulomas. The chemokine
CXCL-10 has been singled out as a powerful biomarker to
distinguish active and latent TB from unexposed individuals
(48). Expression of CXCL10 was higher in infected MDSCs
compared toMDMs. Levels ofCCL5 transcripts were comparable
in the cells under investigation. This led us to investigate the
phagocytic capacity of the two cell types. Bacillary burdens were
higher in MDSCs after 4 h of H37Rv infection (Figure 4B).
Interestingly, the higher bacterial load in MDSCs did not result
in increased Mtb replication over time (observed at 24, 48, and
72 h) (Figures 4C,D). The lower replication of Mtb in MDSC
monocultures and the opposite findings in case of IVGLSs
(Figures 2K, 4D, respectively), suggests that MDSCs regulate
Mtb replication within IVGLSs primarily through interactions
with other immune cell types. Heightened transcription for IL6
and IL10 in MDSCs despite of lower bacterial replication resulted
in more abundant cytokine concentrations in supernatants
after 24 h of infection (Figure 4E). Thus, MDSCs have the
ability to shift the balance of soluble mediators at the site
of infection toward suppressive and regulatory cytokines, by
releasing high amounts of IL-10 and IL-6. BCG resulted in
similar patterns of IL-6 and IL-10 release, which further suggests
that conserved pattern recognition receptors rather than unique
virulence factors affected cytokine abundances in mycobacteria-
infected MDSCs (Supplementary Figure 7). Further supporting
this assumption, MDSCs isolated from TB patients secreted
IL-6 and IL-10 after PPD stimulation (Figure 4F). The data
emphasizes that MDSCs purified from human TB patients are
similar with in vitro generated MDSCs with regard to their
cytokine patterns induced by mycobacterial stimulation.
MAP Kinase and PI3K Pathways Play
Distinctive Roles in Cytokine Secretion in
MDSCs and MDMs With MAPK Controlling
Mycobacterial Replication in
IVGLSs-MDSCs Co-cultures
We further investigated the signaling pathways that contribute
to differential cytokine release in MDSCs upon Mtb infection
and focused on IL-6 and IL-10. Mycobacteria are recognized by
various pattern recognition receptors (PRRs), including TLRs
(TLR-2, TLR-4 and TLR-9) and C-type lectin receptors, to name
a few (49). These events activate distinct mitogen-activated
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FIGURE 4 | MDSCs secrete more abundant inflammatory and regulatory cytokines compared to MDMs upon Mtb infection. (A) Transcript abundances for cytokines
and chemokines in naïve and at 4 h post Mtb infection (MOI 20) in MDSCs and MDMs were calculated for each donor compared to pooled data of all individuals using
the Fluidigm platform (presented as fold change values). (B) Phagocytosis of Mtb (MOI 20) at 4 h post infection was assessed by plating CFUs for both cell types.
(C) Bacillary loads at 24 h post Mtb infection (MOI 10). (D) Fold growth of Mtb (MOI 10) was calculated for 48 and 72 h by dividing CFU counts by respective 4 h
counts. (E) IL-6 and IL-10 were measured from cell-free 24 h supernatants of Mtb-infected (MOI 10 and MOI 20) MDSCs and MDMs by ELISA. (F) IL-6 and IL-10
were measured from PPD stimulated MDSCs isolated from TB patients. Each symbol corresponds to a single donor, shown are median±IQR. Data are pooled from 2
independent experiment (n = 5 individuals) (A), 4 independent experiments (n = 12 individuals) (B), 3 independent experiments (n = 8 individuals) (C), 2 independent
experiments (n = 6 individuals) (D), 3 independent experiments (n = 9 individuals) (E) and 6 independent experiments (n = 7 individuals) (F); two-way ANOVA with
Bonferroni correction (A) and paired Student’s t-test (B–F), *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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protein kinases (MAPK) and nuclear factor kappa B (NF-
κB) for the generation of cytokines (50, 51). Mtb infection
induced significantly higher phosphorylation of p38, ERK1/2,
JNK, and p65 in MDSCs compared to MDMs, demonstrating
that activation of MAPKs and NF-κB pathways was elevated
in MDSCs (Figures 5A,B,D). Comparable results were achieved
irrespective of the FCS starvation prior to infection (data not
included). LPS, which is a bona-fide TLR-4 agonist, resulted
in comparable activation of ERK and p38 pathways in MDSCs
and MDMs (Figures 5C,D), therefore indicating that differences
in MAPKs activation were specific for mycobacterial infection.
Higher activation of MDSCs after mycobacterial infection might
be a coordinated event with their high phagocytic capacity;
however, early divergence in the magnitude and specificity of the
signaling events rather suggest cell specific differences.
To further establish which of these pathways specifically
contributed to heightened IL-6 and IL-10 secretion,
MDSCs/MDMs were pre-treated with various inhibitors
and cytokine levels were measured at 24 h post Mtb infection
(Figures 6A–C). At low concentration of NF-κB inhibitor, IL-6
production in MDSCs was significantly inhibited (Figure 6A).
However, IL-6 production in MDMs was only reduced by
high concentration of inhibitors. The AP-1 inhibitor SR11302
reduced IL-6 secretion from both cell types (Figure 6A).
Similar inhibition activity for IL-6 was displayed by another
AP-1 inhibitor, Tanshinone IIa (Supplementary Figure 8). We
observed that IL-10 secretion was furthermore regulated in
MDSCs and MDMs by the afore-mentioned factors. These data
suggest that both NF-κB and AP-1 contributes to IL-6 and IL-10
production in MDSCs.
To further delineate whichMAPKs are involved, we employed
specific ERK1/2 and p38 inhibitors. We found that single p38
or ERK1/2 inhibition did not alter IL-6 production in MDSCs
(Figure 6B). However, the combination of p38 and MEK1/2
inhibitors significantly reduced IL-6, demonstrating that p38 and
ERK1/2 mutually regulate IL-6 production in MDSCs. In MDMs
single p38 inhibition reduced IL-6 release. IL-10 production from
MDSCs was primarily inhibited by combination of p38 and
MEK1/2 inhibitors. Of note, the differential outcomes of selective
pathway inhibitors were associated with variable activation of
corresponding signaling molecules in the two cell types and not
imprinted by distinct cellular viability. There was no significant
induction of cell death in either of cell types by various inhibitors
at 1 and 5µM concentrations (Supplementary Figure 9). We
further observed significant increase in IL-6 secretion upon
inhibition of the PI3K pathway by Wortmannin in MDMs
(Figure 6C). However, there was no effect of PI3K inhibition
on IL-6 production by MDSCs. PI3K inhibition by LY294002
reduced IL-10 secretion from both cell types, though more
significantly from MDSCs. This may reflect contribution of the
PI3K through GSK3-AP-1 (52) or via activation of ERK (53, 54)
for IL-10 production afterMtb infection.
Inhibitors of p38 andMEK1/2 applied at 1µMconcentrations
reduced Mtb growth specifically in MDSCs-IVGLSs co-cultures
(Figure 7), thereby indicating that these signaling pathways
likely control the IL-10 release and the subsequent Mtb growth.
Taken together, our data indicate that MDSCs employ both
p38 and ERK1/2 and hence activate AP-1/NF-kB for IL-6 and
IL-10 production with impact on bacterial containment within
granuloma-like structures.
MDSCs Upregulate PD-L1 to Regulate
CD3+ Lymphocyte Proliferation and Leave
Mtb Growth Unchanged
Neutralization of IL-10 reduced bacillary growth within IVGLSs,
however we also observed that MDSCs and MDMs both
required direct T-cell contact to promote bacterial growth
(Figure 8A). We quantified levels of PD-L1, which is known
to be upregulated on tumor-infiltrating MDSCs (55, 56) and
contributes to exhaustion of T-cell immunity by cell-cell contact
(57). PDL1 transcripts were more abundant in steady state in
MDSCs compared to MDMs and the Mtb infection further
upregulated expression of this gene in MDSCs (Figure 8B).
We determined the PD-L1 surface expression on cells purified
from co-cultures of MDSCs/MDMs with IVGLSs. Although
the surface expression (gMFI) of PD-L1 was similar for
MDSCs and MDMs (CFSE-labeled), the frequencies of PD-L1
expressing cells were higher in case of IVGLSs supplemented with
MDSCs compared with cultures receiving MDMs (Figure 8C),
suggesting a possible contribution of this co-regulatory molecule
to immune suppression. To investigate the outcome of this
regulation on T-cell responses and Mtb growth, neutralizing
antibodies against PD-L1 were employed. This treatment
resulted in more abundant CD3+ lymphocytes, however the
overall growth of Mtb within IVGLSs remained unchanged
(Figures 8D,E). Thus, Mtb growth in IVGLSs is regulated
via contact-dependent mechanisms and MDSCs employ co-
inhibitory receptors to regulate lymphocyte survival and/or
replication, but neutralization of PD-L1 alone is insufficient
to restrict bacterial growth. It has been reported that PD-L1
blockade may not reduce the suppressive activity of MDSCs (58),
therefore it remains to be established which specific contact-
dependent interactions of MDSCs with cells within granulomas
are decisive for mycobacterial survival.
DISCUSSION
Using in vitro differentiated MDSCs we demonstrated that this
monocytic subset readily phagocytosed Mtb, albeit allowing
reduced bacillary replication in monocultures, abundantly
released IL-10 and employed this cytokine for promoting growth
of Mtb within IVGLSs. MDSCs have been recently described in
TB (13–15, 17–23); however particularly in humans outcome of
their direct interactions with Mtb as well as their roles at the site
of pathology remain enigmatic. Our study unveils responses of
MDSCs to virulent mycobacterial infection and proposes roles of
MDSCs in granuloma progression. Granulomas in TB function
to contain Mtb, but may also facilitate bacterial replication
within and drive disease progression upon caseation (8). We
hypothesized that MDSCs alter granuloma stability. Using an in
vitro model for human granulomas we observed that MDSCs,
in contrast to MDMs, promoted expansion of such multicellular
structures and Mtb replication. The sera employed for MDSC
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FIGURE 5 | Mtb preferentially activates MAPK and NF-κB in MDSCs. Protein levels of p38, ERK1/2, JNK, and NF-κB and their phosphorylated counterparts at
various time points post Mtb infection (MOI 20) (A,B) or LPS stimulation (25 ng/ml) (C). Densitometry of the western blots was performed using ImageJ, values are
plotted and normalized using actin. Data are representative of 2 independent experiments (n = 3–5 individuals) (A, B, Mtb D), 3 independent experiments (n = 3–7
individuals) (C, LPS D). Each symbol corresponds to a single donor, shown are median ± IQR, paired Student’s t-test, *p ≤ 0.05, **p ≤ 0.01.
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FIGURE 6 | Abundant IL-6 and IL-10 release by MDSCs upon Mtb infection are regulated by NF-κB and MAPK pathways. IL-6 and IL-10 were measured in cell-free
culture supernatants from Mtb-infected cells (MOI 10) by ELISA (A–C). Cells were treated with indicated inhibitors and supernatants were collected at 24 h post
infection. Each symbol corresponds to a single donor, shown are median ± IQR. Data are pooled from 3 independent experiments (n = 6–8 individuals); one-way
ANOVA with Dunn’s multiple correction or Wilcoxon test (if only 2 conditions were available), *p ≤ 0.05 and **p ≤ 0.01, ***p ≤ 0.001.
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FIGURE 7 | Interference with MAPK restricts bacterial replication in MDSCs co-cultured IVGLSs. Selected concentrations of inhibitors were added to co-cultures of
IVGLSs and MDSCs/MDMs at the time of addition of the myeloid cells, that is day 5 post IVGLSs generation. CFUs were estimated after 48 h of co-culturing. Each
symbol corresponds to a single donor, shown are median±IQR. Data are pooled from 2 independent experiment (n = 6 individuals); one-way ANOVA with Dunn’s
multiple correction [for conditions of (i) IVGLSs, (ii) MDSC co-cultures, and (iii) MDM co-cultures], ***p ≤ 0.001, ****p ≤ 0.0001. Paired Student’s t-test was performed
only for untreated conditions.
generation may however modulate their capacity to alter
granuloma size as expansion of granuloma-like structures upon
hsMDSCs addition was inconclusive. While Mtb preferentially
replicates in MDMs, MDSCs affect growth of bacteria within
granulomas via IL-10. Interestingly, in vitro granuloma-like
structures generated from latent TB individuals develop faster,
are larger and better in controlling mycobacterial replication
(42). This appears counterintuitive in view of our findings as
LTBI individuals present, albeit at very low frequencies, MDSCs
in their blood (23). In LTBI patients potent antigen specific T-
cell responses may overcome the effects of scantly detectable
MDSCs. Alternatively, granuloma-like structures lack MDSCs
under the experimental conditions applied by Guirado et al.
(42). Considering our study design and the fact that blood
donors included in analyses were Mtb naïve, based on regional
epidemiological data, it is difficult to conclude on how scant
MDSCs in LTBI individuals would affect IVGLSs size and
bacillary containment. The current experimental setupmimicked
recruitment of MDSCs to developing granulomas, as it could
occur in active TB. Our observations highlight that MDSCs (i)
could be regulators of granuloma biology, (ii) employ soluble
factors and direct cell-to-cell contact to enable Mtb growth, (iii)
specifically activate MAPK and NF-κB pathways in response
to mycobacteria to regulate cytokine release, and (iv) poorly
support intrinsic Mtb replication yet may contribute to bacillary
persistence.
IFN-γ and TNF-α are associated with protective immunity,
both in mice and humans and sufficient TNF-α is required for
maintenance of granuloma structure and limits reactivation of
latent TB. Both cytokines are secreted by CD4+ and CD8+ T-cells
as well as by additional lymphocyte subsets, however deficiency
of the CD4+ lymphocytes cannot be compensated for in TB
(2). The ability of naïve and Mtb-infected MDSCs to suppress
CD4+ and CD8+ lymphocyte proliferation, as observed upon
polyclonal stimulation and co-culture, suggested that they could
alter frequencies and products of these lymphocyte populations.
Using IVGLSs, we could not detect any impact of the MDSCs
on the overall abundances of IFN-γ and TNF-α. This may
indicate that the MDSCs do not alter antigen specific cytokine
release, or alternatively that sources of these cytokines inside in
vitro generated granuloma-like structures were unresponsive to
MDSCs. While we measured soluble TNF-α aiming to ascertain
a possible role in IVGLS stability, a role for transmembrane
TNF in human MDSCs, including suppression of lymphocytes,
as demonstrated in mice (22), cannot be excluded. Irrespective
of their suppressive mechanisms, human MDSCs did not
modify abundances of TNF-α in IVGLSs. Suppression of T-cell
proliferation through MDSC-derived reactive oxygen radicals
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FIGURE 8 | Numbers of CD3+ cells but not Mtb growth are regulated via PD-L1 in IVGLSs-MDSCs co-cultures. (A) Bacterial loads in IVGLSs at 48 h following
addition of MDSCs/MDMs with or without direct contact (using trans wells), that is at day 7 post IVGLSs generation. (B) PDL1 expression in monocultures of MDSCs
and MDMs at 4 h post Mtb infection (MOI 20). (C) CFSE-tracked MDSCs or MDMs were co-cultured with IVGLS and PD-L1 surface expression was monitored in
CFSE− and CFSE+ fractions of cells from each culture condition, where CFSE− cells represent myeloid cells of IVGLSs present before initiation of the co-cultures.
(D) Frequency of CD3+ T-cells at day 7 IVGLSs, that is after 48 h IVGLS post co-culturing with MDMs/MDSCs, with or without simultaneous PD-L1 neutralization
(10µg/ml αPD-L1 or isotype control). (E) Day 7 bacterial loads in IVGLSs wells and applying for the last 48 h PD-L1 neutralization and MDSC co-culturing. Data are
pooled from 2 independent experiment (n = 5 individuals) (B) and (n = 6 individuals) (A,C–E), shown are median±IQR; two-way ANOVA with Bonferroni correction
(B) and paired Student’s t-test (A,C–E), *p ≤ 0.05, **p ≤ 0.01, ****p ≤ 0.0001.
may occur during mycobacterial infection. In mice, nitric
oxide (NO) released by monocytic Ly-6G−Gr-1+ cells and
IL-1R-dependent NO production by CD11b+Ly-6CintLy-6G−
cells control lymphocyte proliferation (18, 19). NO is hardly
measurable in mycobacteria-infected human macrophages in
normoxic environment (59), however propensity of human
MDSCs to produce NO and ROS and their functional relevance
should be considered.
Addition of MDSCs to IVGLSs increased abundances of the
immunosuppressive cytokine IL-10. This cytokine is present in
lungs of TB patients (46), inhibits phagosomematuration inMtb-
infected macrophages (60), suppresses CD4+ T-cell proliferation
(61) and initiates type I interferon responses (6). Depletion of
IL-10 promotes resistance to TB in mice by inducing more
infiltrating CD4+ T-cells in infected lungs (62). Many immune
cells secrete IL-10, however the source of this cytokine in
TB granulomas has not been clearly established. We showed
that human MDSCs, including cells ex vivo purified from TB
patients, abundantly produced this cytokine upon mycobacterial
stimulation. Using in vitro generated MDSCs we demonstrated
that IL-10 production is primarily controlled by selected MAPKs
and NF-κB. Whether sera source used for MDSC differentiation
impacts on the IL-10 release and the upstream pathways
remains to be verified. A role for IFN-I in regulation of IL-
10 in MDSCs cannot be excluded. We detected more abundant
transcripts of CXCL10, a bona-fide gene regulated by IFN-I, in
MDSCs. By releasing IL-10, MDSCs partly regulatedMtb growth
within IVGLSs. An autocrine regulation is unlikely because
Mtb replication within MDSC monocultures was reduced.
Replication rates were much lower in MDSCs than those
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observed in MDMs despite the former showing a high capacity
to phagocytize Mtb. Although MDSCs show less phagocytosis
of and consecutively favor survival of other microbes, notably
Klebsiella penumoniae (63), more investigations are necessary
to identify survival mechanisms of Mtb inside MDSCs. MDSCs
may affect responsiveness of other myeloid cells within IVGLSs,
for example macrophages containing mycobacteria. Control
of microbicidal activity of myeloid cells via MDSC-derived
IL-10 has been reported recently (63). Alternatively, MDSCs
can also decrease MHC-II expression of macrophages (64).
Macrophages are also reported to enhance secretion of IL-10
by MDSCs and in return MDSCs down-regulate in a contact-
dependent manner IL-12 production by macrophages in tumor
models (65). Whether such mechanisms are operative in IVGLSs
awaits clarification. Mtb is able to replicate extracellularly
(66, 67) and thus inhibition of phagocytosis, as noted for K.
pneumoniae (63), would again favor bacterial growth in presence
of MDSCs. Of note, within IVGLSs MDSC undergo rather
necrosis. Although we do not have evidence regarding infectivity
of the necrotic MDSCs, cytolysis could precondition Mtb for
accelerated replication (67, 68).
Human MDSC, like their murine counterparts (17), released
abundant IL-6, albeit without significant impact on overall
concentration in IVGLSs. This cytokine is elevated in advanced
pulmonary TB patients (69), it positively correlates with MDSC
frequencies in malignant cancer patients (70) and drives
mobilization or expansion of MDSCs (71, 72). Therefore,
high secretion of IL-6 by mycobacteria-infected MDSCs could
represent a positive feedback for maintenance and recruitment
of MDSCs at the site of infection. Antitumor T-cell response and
IFN-γ secretion are both restored by administration of anti-IL-6
receptor antibody with subsequent down-regulation of MDSCs
(73). Such a strategy to limit MDSC generation may be advisable
in TB, since IL-6 inhibits detrimental IFN-I in TB (74) and
induces IFN-γ during early mycobacterial infection (75). IL-6
specific contributions to TB granulomas, notably lesion stability,
and outcome remain undefined.
Activation of MDSCs in various cancer models involves
multiple signaling pathways, including RAF/MAPK, PI3K/AKT,
JAK/STAT, and NF-κB (76). In sepsis, TLR4 independent and
myeloid differentiation primary response protein 88 (MyD88)
dependent activation controls MDSC functions (77). We
observed faster, and more pronounced activation of several
MAPKs and NF-κB pathways inMtb-infected MDSCs compared
to MDMs. Differences in signaling kinetic have not been
detected for LPS, despite upregulation of CD14 on MDSCs
in an inflammatory environment (78). While MDSCs indeed
present more abundant signaling molecules at steady state,
further studies should clarify the precise upstream receptors
which sensemycobacterial cues and promptly switch on signaling
in MDSCs. In mice MyD88-dependent recruitment of MDSCs
and IL-1R-dependent iNOS activation affects T-cell immunity
following BCG vaccination (18). Moreover, murine MDSCs
produce IL-1 (17) and could in autocrine or paracrine way
affect signaling activity. Expression and involvement of the
MyD88/IL-1R in human MDSC responses to mycobacteria
awaits clarification. In our study, MAPKs and NF-κB pathways
cumulatively drive secretion of IL6 and IL-10 afterMtb infection.
We observed that MDSCs are more sensitive to NF-κB mediated
IL-6 inhibition and coordinated inhibition of p38 and MEK1/2 is
required to inhibit secretion of IL-6 and IL-10 in MDSCs. PI3K
inhibition differentially upregulated IL-6 secretion by MDMs
but not by MDSCs, whereas IL-10 secretion by MDSCs was
reduced significantly. This suggests that the two cell types
exhibit preferential signaling for targeted cytokine release upon
mycobacterial sensing. Further studies, including identification
of subcellular localization of Mtb in MDSCs, are required to
delineate precise mechanisms of MDSC activation in TB.
Therapies targeting the PD-1/PD-L1 pathway, or checkpoint
blockade inhibitors, represent a breakthrough in immunotherapy
and improve clinical outcomes in certain cancers substantially
(79). This strategy has been extended to chronic infectious
diseases. Checkpoint inhibitors improve HIV-1 specific
immunity in a subset of patients and promote clearance of
hepatitis B virus in murine models of persistent infection
(80, 81). MDSCs express PD-L1 and its blockade restores T-cell
activation mediated by tumor infiltrating MDSCs with down
regulation of IL-6 and IL-10 (82). However, other studies have
failed to validate PD-L1-mediated suppression by MDSCs
(58, 83, 84). We found that PDL1 is upregulated in Mtb-infected
MDSCs and when IVGLSs are co-cultured with MDSCs, more
PD-L1 positive cells are present in the system. Checkpoint
blockade therapy of IVGLSs co-cultured with MDSCs resulted in
more abundant CD3+ T-cells, suggesting increased lymphocyte
viability and/or proliferation in absence of the PD-1/PD-L1
co-inhibitory axis. Yet, PD-L1 neutralization left mycobacterial
growth unchanged, despite higher lymphocyte frequencies.
The relevance of PD-1 for T-cell control of TB has been
demonstrated in murine model (85) and recent studies in active
TB patients suggested that the antagonists to PD-1 rescue
suppressive activity of MDSCs, primarily by interfering with the
PD-1/PD-L2 cross-talk (86). These investigations also show that
IFN-γ restricts suppressive capacities of human MDSCs if the
cytokine is available during generation of MDSCs. Although in
our system MDSCs exhibited potent lymphocyte suppression
post-generation, it cannot be excluded that the presence of
IFN-γ in IVGLSs may limit suppression via PD-1. Possibly other
cell-cell contact mechanisms, independent of PD-1 impact the
bacillary growth in presence of MDSCs. The cytolytic capacities
of lymphocytes deserve further investigations. Moreover,
MDSCs expand regulatory T-cells (87) and these may also affect
anti-mycobacterial defense.
Our results offer novel views on cellular diversity and
functions of myeloid cell subsets in granulomas. The granuloma
microenvironment in TB patients contains factors which could
reprogram recruited monocytes into MDSCs, notably cytokines
such as GM-CSF and IL-6 (84), as well as lipid mediators,
including PGE2 (88, 89). In a pro-inflammatory environment,
MDSC differentiation may also encompass licensing by GM-CSF
and IFN-γ leading to stable expression of suppressive factors, as
reported for CD14+ monocytes (90). These soluble mediators
are present in TB lesions and may contribute to local MDSC
genesis. Alternatively, MDSCs may be generated in the bone
marrow in active TB, as demonstrated in murine models (20)
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and populate granulomas following their release into blood
stream. In situ genesis and differentiation in bone marrow are
also not mutually exclusive processes. Whether the presence of
MDSCs in TB granulomas drives pathology or if these cells
are a consequence of unresolved inflammation, subsequently
exacerbating tissue damage remains to be established. Our
data reveal that in vitro generated human MDSCs readily
phagocytosed mycobacteria, yet they do not offer a niche for
fast replication, as macrophages do. Effects of sera used for
generation of MDSCs on Mtb permissiveness was not addressed
in the current study. Moreover, these findings need validation
with MDSCs isolated from the site of infection in TB patients.
It is tempting to speculate that MDSCs have dual detrimental
roles in TB, supporting bacterial persistence inside granulomas;
via intrinsic mechanisms, which await clarification and bacterial
replication; via paracrine mechanisms including release of IL-
10 and cell to cell contact. Such scenarios may arise in other
chronic infectious diseases as well. While we largely focused
on monocytic suppressor cells, involvements of granulocytic
MDSCs in TB may as well be critical for the disease outcome,
including granuloma features. In murine TB both types of
MDSCs exert suppressive activity and in humans particularly
granulocytic MDSCs expand during active TB (14). Clarifying
roles and outcomes of direct interactions between granulocytic
MDSCs andMtb warrant future investigation.
By promoting Mtb replication within IVGLSs, monocytic
MDSCs qualify as potential targets for host directed therapies
(HDT). Identification of the signaling pathways driving
generation of regulatory cytokines further positions MDSCs
as druggable candidate. Such therapies in TB are spearheaded
by ongoing work focused on MDSCs in cancer (91). Various
drug classes could be tested in fast-tracked clinical trials and
eventually be repurposed for HDT in TB.
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